Grant: Doctoral: Vanier Canada Graduate Scholarships
McGill University
$150,000.00
Using real-time electronic health information from a multi-national pharmacosurveillance system to assess the safety and effectiveness of oral hypoglycemic drugs among patients with type 2 diabetes
FY 2011-12
Summary
Many new drugs are appearing on the market to treat common chronic diseases such as heart disease and type 2 diabetes. In the pre-market stage, new drugs are often tested on small, unrepresentative samples of patients. As a result, the effects of these drugs on people of different ethnicities and gender, as well as people with different clinical conditions are often unknown. Post-market surveillance of new drugs is therefore important in order to monitor their safety and effectiveness after they enter the market. Voluntary reporting is one of the most common methods of post-market surveillance, but this method is insufficient as it only captures 2%-10% of adverse drug events (ADE). This indicates the need for improved methods of post-market surveillance.
In recent years, there has been a call to explore ways in which electronic health records (EHR) could be used for post-market surveillance of new drugs. EHRs are valuable resources because they contain rich, clinical information on prescribed therapies, medical diagnoses, and lifestyle factors that is updated in real-time. EHRs could therefore be used to create a real-time surveillance system that identifies large cohorts of people taking different drugs and monitors them for important clinical outcomes. This would allow researchers to assess the safety and effectiveness of new drugs in a timely fashion and compare available drug therapies on the market.
In this study, I will be using EHRs from a real-time multi-national pharmacosurveillance system to assess the safety and effectiveness of different types of oral hypoglycemic drugs in patients with type 2 diabetes. This surveillance system will monitor millions of people in Canada, the USA, and England, and allow for a robust analysis of the benefits and risks of different drug types. The results from this study will hopefully help physicians and patients improve the selection and use of oral hypoglycemic drugs and reduce the occurrence of ADEs.
Department
Program
Doctoral: Vanier Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
247718
Name
Wong Jenna
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Using real-time electronic health information from a multi-national pharmacosurveillance system to assess the safety and effectiveness of oral hypoglycemic drugs among patients with type 2 diabetes
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Medical Informatics; Meta-Analysis Methods; Non-Parametric Models; Pharmacosurveillance; Risk Prediction Models; Survival Analysis; Time-Dependent Covariates
Abstract
Many new drugs are appearing on the market to treat common chronic diseases such as heart disease and type 2 diabetes. In the pre-market stage, new drugs are often tested on small, unrepresentative samples of patients. As a result, the effects of these drugs on people of different ethnicities and gender, as well as people with different clinical conditions are often unknown. Post-market surveillance of new drugs is therefore important in order to monitor their safety and effectiveness after they enter the market. Voluntary reporting is one of the most common methods of post-market surveillance, but this method is insufficient as it only captures 2%-10% of adverse drug events (ADE). This indicates the need for improved methods of post-market surveillance.
In recent years, there has been a call to explore ways in which electronic health records (EHR) could be used for post-market surveillance of new drugs. EHRs are valuable resources because they contain rich, clinical information on prescribed therapies, medical diagnoses, and lifestyle factors that is updated in real-time. EHRs could therefore be used to create a real-time surveillance system that identifies large cohorts of people taking different drugs and monitors them for important clinical outcomes. This would allow researchers to assess the safety and effectiveness of new drugs in a timely fashion and compare available drug therapies on the market.
In this study, I will be using EHRs from a real-time multi-national pharmacosurveillance system to assess the safety and effectiveness of different types of oral hypoglycemic drugs in patients with type 2 diabetes. This surveillance system will monitor millions of people in Canada, the USA, and England, and allow for a robust analysis of the benefits and risks of different drug types. The results from this study will hopefully help physicians and patients improve the selection and use of oral hypoglycemic drugs and reduce the occurrence of ADEs.
Competitiondate
201111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Wong, Jenna
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~